Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio.

PST-611 is a first in class non-viral vectorized therapy for the treatment of dry AMD/GA coding for human transferrin. PulseSight Therapeutics SAS presented new data on its lead program PST-611, a DNA ...

Clinical associations, imaging strategies and establishing a differential diagnosis from pseudopapilledema. This article aims to discuss optic disc drusen (ODD, or pseudopapilledema) in the context of ...

Clinical associations, imaging strategies and establishing a differential diagnosis from pseudopapilledema.

The Healthcare Private Equity team has advised Retina Consultants of America (RCA) and Webster Equity Partners in the sale of RCA to Cencora. The Healthcare Private Equity team has advised Retina ...

This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD). The US FDA has cleared an investigational new ...

"The De Novo authorization established Valeda as the first device for treatment of dry AMD patients with vision loss and creates a threshold for this novel class of photobiomodulation (PBM) devices ...

A recent cohort study revealed low adoption of FDA-approved AI-based diabetic retinopathy detection, with less than 5% of diabetic patients receiving ophthalmic imaging. Researchers emphasize the need ...

Dr. Mammo discussed this evolution and how to choose patients who would best benefit from GA therapy. Clinicians’ attitudes toward geography atrophy (GA) and treatment have been changing in the short ...

The company noted that its GalOmic pipeline includes ETX-407 for the treatment of dry age-related macular degeneration (AMD). e-therapeutics plc, shared business updates across a variety of areas.

Katherine Talcott, MD, discussed other potential therapies and their mechanisms of action being evaluated in clinical trials at the OSN New York 2024 conference. There is a great need for more ...